Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2/3 study of tafasitamab (MOR00208) plus bendamustine versus rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma in patients ineligible for high-dose chemotherapy and autologous stem cell transplant
MOH_2017-01-30_000042Phase 3Recruiting
- Sponsor
- MorphoSys AG
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Tafasitamab + bendamustine with Rituximab + bendamustine (2 arms). Started Jun 2016; status: recruiting.
02
Drugs
tafasitamabbendamustinerituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2017-01-30_000042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-30_000042.